News & Trends - Biotechnology
Aussie biotech lands second patent for anti-cancer treatment

Biotech News: An Australian biotech company has locked in another patent for its cancer-treatment.
Immutep’s new US patent builds on the protection provided by the parent patent in December 2020, and are directed to methods of treating cancer by administering Immutep‘s lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a PD-1 pathway inhibitor.
According to the claims, the PD-1 pathway inhibitor is either MSD’s Keytruda (pembrolizumab) or Bristol Myers Squibb’s Opdivo (nivolumab).
The expiry date of the patent is January 2036.
“We are very pleased to add another United States patent to our expanding patent portfolio, especially in this case, because of its direct relevance to our clinical development programs. These patent grants are important as they underpin ongoing investment in clinical development of efti and allow us to confidently engage in business development discussions,” said Marc Voigt, CEO of Immutep.
A further divisional application has been filed to pursue other aspects of the invention, including combinations where the PD-1 pathway inhibitor is a PD-L1 inhibitor.
The lead product candidate eftilagimod alpha (LAG-3Ig or IMP321), a first-in-class antigen presenting cell (APC) activator, is currently being investigated in clinical trials as a treatment (in combination with chemotherapy or immune therapy) in partnership with GSK in ulcerative colitis and in partnership with Novartis for solid tumours, blood cancer and breast cancer.
News & Trends - Pharmaceuticals

Government’s long-awaited response to The New Frontier report unveiled after two-year wait
Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]
MoreNews & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’
Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]
MoreNews & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years
Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]
More